GLAUKOS Corp (GKOS) Latest Company News

Oct 9, 2026, 17:17 UTC
GLAUKOS Corp shares declined 6.3% following the licensing news.
Source:
- zacks.com
Oct 9, 2026, 16:49 UTC
GLAUKOS Corp reported successful topline outcomes from its latest Phase 4 clinical study of a novel eye therapy, describing superior intraocular pressure reduction.
Source:
- benzinga.com
Oct 9, 2026, 11:00 UTC
Glaukos announced positive topline results from its Phase 4 GLK-101-04 trial evaluating iDose TR with cataract surgery versus cataract surgery alone in patients with open-angle glaucoma.
Source:
- businesswire.com
Oct 8, 2026, 11:00 UTC
Glaukos announced an exclusive license agreement with RevOpsis Therapeutics to develop and commercialize RO-104 for retinal diseases.
Source:
Oct 7, 2026, 20:05 UTC
GLAUKOS Corp announced positive topline results from a long-term Phase 3 extension study evaluating Epioxa’s durability, visual outcomes and safety in treating keratoconus.
Source:
- businesswire.com
- benzinga.com
Oct 7, 2026, 11:00 UTC
GLAUKOS Corp announced that it plans to release its third-quarter 2026 financial results after market close on October 28, 2026.
Source:
- businesswire.com
Sep 23, 2026, 11:00 UTC
Glaukos Corporation launched the "Could it be KC?" keratoconus awareness campaign in partnership with NBA champion Stephen Curry, with expanded activities planned for 2027.
Source:
- businesswire.com
Jul 29, 2026, 23:26 UTC
Glaukos Corporation reported its second quarter 2026 financial results, posting a net loss of $0.14 per share, which beat the Zacks Consensus Estimate of a loss of $0.28 per share and improved from a loss of $0.24 per share in the same quarter a year ago.
Source:
Jul 27, 2026, 11:00 UTC
Glaukos completed patient enrollment in its U.S. 510(k) pivotal study for the PRESERFLO MicroShunt in adult patients with primary open-angle glaucoma.
Source:
- businesswire.com

GKOS

GLAUKOS Corp shares declined 6.3% following the licensing news.

GLAUKOS Corp reported successful topline outcomes from its latest Phase 4 clinical study of a novel eye therapy, describing superior intraocular pressure reduction.

Glaukos announced positive topline results from its Phase 4 GLK-101-04 trial evaluating iDose TR with cataract surgery versus cataract surgery alone in patients with open-angle glaucoma.

Glaukos announced an exclusive license agreement with RevOpsis Therapeutics to develop and commercialize RO-104 for retinal diseases.

GLAUKOS Corp announced positive topline results from a long-term Phase 3 extension study evaluating Epioxa’s durability, visual outcomes and safety in treating keratoconus.

GLAUKOS Corp announced that it plans to release its third-quarter 2026 financial results after market close on October 28, 2026.

Glaukos Corporation launched the "Could it be KC?" keratoconus awareness campaign in partnership with NBA champion Stephen Curry, with expanded activities planned for 2027.

Glaukos Corporation reported its second quarter 2026 financial results, posting a net loss of $0.14 per share, which beat the Zacks Consensus Estimate of a loss of $0.28 per share and improved from a loss of $0.24 per share in the same quarter a year ago.

Glaukos completed patient enrollment in its U.S. 510(k) pivotal study for the PRESERFLO MicroShunt in adult patients with primary open-angle glaucoma.